Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Dow
Healthtrust
Colorcon
Fish and Richardson
Baxter
Cipla
Merck
Cerilliant

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,107,921

« Back to Dashboard

Summary for Patent: 9,107,921
Title:Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Abstract: A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm.about. for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm.about. provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.
Inventor(s): Giliyar; Chandrashekar (North Maple Grove, MN), Nachaegari; Satish Kumar (Salt Lake City, UT), Machiappan; Chidambaram (Salt Lake City, UT), Patel; Mahesh V. (Salt Lake City, UT), Venkateshwaran; Srinivasan (Salt Lake City, UT)
Assignee: Spriaso LLC (Salt Lake City, UT)
Application Number:14/555,043
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 9,107,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Spriaso Llc CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,107,921

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,066,942 Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Federal Trade Commission
Fish and Richardson
Farmers Insurance
Chubb
Dow
UBS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.